Nav: Home

Results of early-stage liver cancer detection using liquid biopsy published in PNAS

March 12, 2019

Highlights:
  • Genetron Health (Beijing) Co. Ltd and National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences published the promising results of their liver cancer early screening study using cell free DNA and protein biomarkers.
  • This product for screening HCC in at-risk populations, will be further validated and then available for use.
  • This methodology is expected to be applied in early screening of other cancer types.
March 12th, 2019, Beijing - Today, Proceedings of the National Academy of Sciences (PNAS) published the results of a pilot study for early detection of liver cancer in a cohort of HBV carriers, who are at risk for developing this disease. This screening technology, known as HCCscreen, relies on detecting a combination of tumor-specific mutations in cell free DNA (cfDNA) and protein markers. This work was a collaborative effort between National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences and Genetron Health (Beijing) Co. Ltd (Genetron). Based on these promising results, assays such as this, after rigorous clinical validation, could be developed into an application for the detection of early-stage liver cancer.

The HCCscreen assay developed in the study uses both specific mutation profiles from plasma cfDNA along with protein biomarkers. The combination of these markers enabled excellent performance of the assay in a cohort of asymptomatic HBV carriers. A total of 331 HBV carriers (with normal alpha-fetoprotein levels and normal ultrasound) were tested using HCCscreen. Among them, 24 subjects were identified as positive and 307 (out of 331) as negative. Furthermore, four out of the 24 individuals with a positive HCCscreen test were later diagnosed as having early stage liver cancer (less than 3 cm) within 6-8 months. The early detection with HCCscreen allows earlier intervention with surgery, which significantly increases the likelihood of cure. On the other hand, none of HCCscreen-negative individuals were diagnosed clinically with liver cancer in the same follow-up period. Therefore, at the time point, this result demonstrated a 17% positive predictive value, a 100% sensitivity and a 94% specificity in this cohort.

One of HCCscreen's core technologies is Mutation Capsule, invented by Genetron, which enables the accurate detection of hot spot mutations, indels and hepatitis B virus (HBV) integrations commonly present in HCC tumors. Besides the biomarkers described in this study, this assay can be further optimized to detect more genetic alterations, such as copy number variations. The optimized assay has been validated in additional cohorts with >93% sensitivity and >98% specificity.

Mr. Sizhen Wang, co-founder and CEO of Genetron, emphasized: "Some developed countries have achieved extraordinary performance in reducing morbidity and mortality of some cancer types, such as colorectal cancer in the United States and gastric cancer in Japan, which need to thank the efficient early screening of the cancers. Genetron is working diligently and would like to launch the product for early screening of liver cancer, therefore, to reduce mortality of liver cancer patients. The similar technology can be adapted and developed to screen other types of cancers after clinical validation, and we are dedicated to providing effective technologies for the early detection of cancer in high-risk populations, as well as in general populations."

With a noninvasive blood test, the liquid biopsy technology can provide important diagnostic indicators for asymptomatic HBV carriers. The research team is currently conducting a larger scale clinical trial to further improve and validate the method.

Background

Liquid biopsy using plasma cell free DNA (cfDNA) mutation profiles has made great progress in recent years, and promising results have been demonstrated in early screening of multiple cancer types.

Patients identified by HCCscreen as being positive for tumor-specific markers in this prospective study were mostly asymptomatic as they had very early stage liver cancer. Compared to the differentiation of healthy individuals and hospitalized cancer patients in retrospective studies, it could be more challenging to distinguish asymptomatic early-stage HCC patients from at-risk individuals, however, the prospective studies could be important to set up the algorithm and threshold with favorable performance in the screening of early HCC, as the screening of HCC most likely happens in the context of high-risk individuals in clinical practice.
-end-
About Genetron Health (Beijing) Co. Ltd

As a leader in cancer precision medicine in China, Genetron is practicing the research and development concept of "exploration, discovery, application and change". Genetron offers cancer researchers and health care providers a full cycle of products and services from prevention to treatment, including risk assessment, early screening, molecular diagnosis, medication guidance, and prognosis monitoring.

Genetron maintains facilities worldwide totaling over 10,000 square meters, with two research and development centers, one in China and one in the United States, and four clinical diagnostic laboratories across China. Genetron is accredited by both CAP and CLIA. The company also has a team of multi-disciplinary experts covering cancer genomics, bioinformatics, pharmacology, and clinical pathology.

Genetron has cooperated with some of the world's top medical and research institutes domestically and internationally on nearly 100 projects and has led many national or local scientific research projects with publications in journals such as Nature Genetics, PNAS, and Nature Communications. Genetron provides both diagnostic products and services to hundreds of scientific research institutions and has served tens of thousands of cancer patients. Its in-depth vision has laid out opportunities both upstream and downstream in the industrial chain for future development.

In the field of diagnosis and treatment, Genetron's products and services cover a spectrum of cancers, including but not limited to the brain, lung, liver, colorectum, bladder, breast, stomach, and thyroid cancers. In the field of cancer screening, Genetron has already developed high sensitivity and specificity technology that is being validated in larger cohorts. The rigorously validated technology platform will hold promise for future earlier cancer screening.

About Cancer Hospital, Chinese Academy of Medical Sciences

The Cancer Hospital of CAMS was founded in 1958, and is the home of the China National Cancer Clinical Medical Research Center, the National Standardized Cancer Diagnosis and Treatment Quality Control Center, and the State Food and Drug Administration certified National Drug Clinical Research Center. It integrates medical education and research and is the authority for the nation's basic research and clinical diagnosis and treatment of cancer. The hospital is in the forefront of the multidisciplinary and standardized comprehensive treatment of various tumors in China. The annual outpatient visits are more than 840,000, and the annual operations is more than 20,000.

The hospital has extensive academic influence internationally and cooperates with the WHO International Agency for Research on Cancer (IARC), the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the MD Anderson Cancer Center. It has signed strategic cooperation agreements with internationally renowned cancer research and treatment institutions such as Mayo Clinic, University of California, Los Angeles (UCLA), and the UK Cancer Institute (CRUK).

About PNAS

Proceedings of the National Academy of Sciences of the United States of America (PNAS) is one of the world's most-cited and comprehensive multidisciplinary scientific journals, which strives to publish only the highest quality scientific research, and papers undergo rigorous peer review and approval by an NAS member before publication. PNAS publishes cutting-edge research, science news, Commentaries, Perspectives, Colloquium Papers, Reviews, and actions of the NAS. The journal's content spans the biological, physical, and social sciences and is global in scope.

To learn more, please visit: http://www.genetronhealth.com
Or send your inquiry to:
Ms. Yuan Tao
Genetron Health (Beijjing) Co. Ltd
Email: yuan.tao@genetronhealth.com

Genetron Health

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#532 A Class Conversation
This week we take a look at the sociology of class. What factors create and impact class? How do we try and study it? How does class play out differently in different countries like the US and the UK? How does it impact the political system? We talk with Daniel Laurison, Assistant Professor of Sociology at Swarthmore College and coauthor of the book "The Class Ceiling: Why it Pays to be Privileged", about class and its impacts on people and our systems.